European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- !exclusive! Jun 2026

A 2020 European study found many tablets failed Ph. Eur. divisibility requirements. The Freedom of Information request regarding UK liothyronine tablets further demonstrates the practical consequences of non-compliance with these rules.

: Differing primarily in disintegration time and surface finish.

| Feature | Ph. Eur. 0478 | USP <701> / <711> | JP (Tablets) | |---------|---------------|--------------------|---------------| | Scope | Uncoated & film-coated only | Includes chewable, buccal, etc. | Broader – includes effervescent | | Dissolution | 2.9.3 with Q-value | <711> with S1, S2, S3 stages | Similar to USP | | Disintegration | Permitted as alternative | Not a substitute for dissolution (except BCS Class I or III) | Permitted | | Friability | Optional unless specified | Mandatory (USP <1216>) | Mandatory | | Hardness | Not required | Not required but common | Not required | European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Standard forms, with film-coated variants specified for thin polymeric layers.

The European Pharmacopoeia (Ph. Eur.) monograph for Tablets (0478) provides a comprehensive set of specifications for the testing and evaluation of tablets. The monograph covers a range of requirements, including appearance, average weight, uniformity of weight, hardness, friability, disintegration, and dissolution. By following these specifications, manufacturers can ensure that their tablets meet the necessary standards for quality, purity, and strength. A 2020 European study found many tablets failed Ph

The monograph begins with a precise definition of what constitutes a "tablet." According to Ph. Eur. 0478, , obtained by compressing uniform volumes of particles or by another suitable manufacturing technique, such as extrusion, moulding or freeze-drying (lyophilisation).

This requirement is so critical that its practical application has been the subject of a European study. The study, conducted by 27 state control laboratories from 22 European countries, found that , underscoring the practical challenges in this area. The uniformity of halved tablets depends heavily on the formulation, geometry, and manufacturing process, embodying the Quality by Design principle where "scorability needs to be built into the tablet". The Freedom of Information request regarding UK liothyronine

The definition is followed by a clear statement of scope. The monograph specifically applies to tablets intended for oral administration. It explicitly does not apply to lozenges, oral pastes, or oral gums. Furthermore, the monograph clarifies that certain tablets, such as those for rectal or vaginal use, are covered by other specific monographs, not by 0478. If justified and authorised, the requirements may also not apply to tablets for veterinary use.

By adopting the standards and guidelines set out in the "Tablets -0478-" monograph, the pharmaceutical industry can ensure that tablets are produced and controlled to a high standard, ultimately benefiting patients and public health.

The Ph. Eur. monograph for Tablets - 0478 is a comprehensive guide that sets standards for the quality of tablets. By following the guidelines set out in the monograph, manufacturers can ensure that their tablets meet the required standards for quality, purity, and strength. The monograph plays a crucial role in ensuring patient safety, increasing confidence in the quality of medicines, and facilitating market authorization. As the pharmaceutical industry continues to evolve, the Ph. Eur. monograph for Tablets - 0478 remains an essential resource for ensuring the quality of tablet formulations.

Chemically assaying individual units (required for potent drugs or low-dose formulations). 2. Disintegration